{"title":"New Concepts in Vitamin D Requirements for Children and Adolescents: A Controversy Revisited.","authors":"Emma M Laing, Richard D Lewis","doi":"10.1159/000486065","DOIUrl":"https://doi.org/10.1159/000486065","url":null,"abstract":"<p><p>North American and European authorities have identified thresholds up to 50 nmol/L serum 25-hydroxyvitamin D (25[OH]D) as optimal for pediatric vitamin D status. These recommendations are relative to skeletal endpoints, as vitamin D plays a pivotal role in bone mineral content (BMC) accretion. Suboptimal vitamin D consumption during youth may therefore hinder BMC acquisition, and contribute to an increased fracture risk. Though vitamin D requirements range between 400 and 800 IU/day, not all children achieve this. To encourage adequate vitamin D consumption, strategies such as supplementation, food labeling, and fortification, are currently being investigated. There is moderate support for the role of vitamin D supplementation on adolescent BMC accrual; however, factors such as age, maturation, population ancestry, and latitude, are not consistently accounted for across studies. Vitamin D is also linked with extraskeletal endpoints (e.g., muscle mass/function, adiposity, and metabolic health) in children, but the cross-sectional data do not necessarily align with results from experimental trials. Based on the evidence currently available, there is no need for a revision of the pediatric vitamin D recommendations at this time. Additional trials are required, however, to build upon the hypothesis-generating observational data, and to provide evidence for future vitamin D requirements across the globe.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"50 ","pages":"42-65"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35960668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Syndrome in Hyperprolactinemia.","authors":"Marianne Andersen, Dorte Glintborg","doi":"10.1159/000486000","DOIUrl":"https://doi.org/10.1159/000486000","url":null,"abstract":"<p><p>The metabolic syndrome (MetS) is a conglomerate of clinical findings that convey into increased morbidity and mortality from type 2 diabetes mellitus (T2D) and cardiovascular disease. Hyperprolactinemia (hyperPRL) is associated with components of MetS, especially during pregnancy. Endogenous levels of sex steroids are high during pregnancy in contrast to untreated or replaced hypogonadism in most patients with a prolactinoma and hypogonadism may confer increased risk of MetS in hyperPRL. Dopamine-D2-agonist therapy can improve MetS in patients with a prolactinoma and lower glucose levels in patients with T2D. HyperPRL is a biomarker for decreased dopaminergic tonus in the hypothalamic-pituitary circuit. Patients with a prolactinoma, patients with schizophrenia and/or T2D often have disturbances in this balance and the finding of lower prolactin (PRL) levels in polycystic ovary syndrome (PCOS) may indicate increased dopaminergic tonus. Recent studies supported that PRL levels within or above reference range may be differently related to MetS. In healthy study populations and in PCOS, PRL levels were inversely associated with metabolic risk markers. Ongoing research on PRL fragments, vasoinhibins, may help explain some of the contradicting findings between prolactin levels and metabolism. Improved knowledge about MetS in hyperPRL can characterize subgroups of patients with hyperPRL, who would not otherwise be considered as candidates for dopamine-D2-agonist therapy such as patients with postpartum cardiomyopathy and postmenopausal women with T2D.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"29-47"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36215379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Complications in Adrenal Insufficiency.","authors":"Grethe A Ueland, Eystein S Husebye","doi":"10.1159/000486004","DOIUrl":"https://doi.org/10.1159/000486004","url":null,"abstract":"<p><p>Pharmacological glucocorticoid treatment is associated with adverse metabolic consequences such as hypertension, overweight, reduced glucose tolerance, diabetes mellitus and ultimately increased mortality in cardiovascular disease. Here we review the evidence of detrimental effects of hormone replacement therapy in adrenal insufficiency (AI). Registry studies indicate increased cardiovascular mortality, hypertension, diabetes, and dyslipidemia in both primary and secondary AI, but when cohorts with carefully characterized patients are studied the picture is less clear, and recently patients with primary AI was reported to have less hypertension and lower body mass index than controls. Whether near physiological replacement therapy increase long-term cardiovascular morbidity and mortality in AI is still unclear.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"104-113"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36216480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Syndrome in Cushing's Syndrome Patients.","authors":"Francesco Ferraù, Márta Korbonits","doi":"10.1159/000486002","DOIUrl":"https://doi.org/10.1159/000486002","url":null,"abstract":"<p><p>Cushing's syndrome (CS), including visceral obesity, dyslipidemia, hypertension and diabetes among its many manifestations, is \"a model\" of metabolic syndrome. Glucocorticoid (GC) excess, through a combination of effects on liver, muscle, adipose tissue and pancreas, increases gluconeogenesis and impairs insulin sensitivity, leading to carbohydrate abnormalities. Dyslipidemia is a common finding in CS as a consequence of GC-related increased lipolysis, lipogenesis and adipogenesis. CS patients experience typical changes in body composition, with fat redistribution resulting in accumulation of visceral adipose tissue. Hypertension, myocardial and vascular abnormalities along with the metabolic changes and the characteristic coagulopathy increase cardiovascular morbidity and mortality. Metabolic syndrome features can persist long after normalisation of cortisol levels.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"85-103"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36216476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Practical Issues in Vitamin D Replacement.","authors":"Robert A Adler","doi":"10.1159/000486068","DOIUrl":"https://doi.org/10.1159/000486068","url":null,"abstract":"<p><p>Practical clinical guidance for vitamin D assessment and management relies on a strong evidence base, but unfortunately there are many deficiencies in our current knowledge. For the general population the Institute of Medicine recommendations are likely to provide adequate vitamin D levels without harms. Thus, most adults should ingest 600-800 IU (international units) in diet and supplements with up to 4,000 IU daily likely to be safe. In certain populations, such as those with osteoporosis or after bariatric surgery, it is important to know the levels of circulating 25-hydroxyvitamin D, but general screening has not been shown to improve health. One expert group has recommended a \"reasonable\" level of 30 ng/mL in those individuals for whom testing is required.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"50 ","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35960670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Syndrome in Polycystic Ovary Syndrome.","authors":"Renato Pasquali","doi":"10.1159/000485995","DOIUrl":"https://doi.org/10.1159/000485995","url":null,"abstract":"<p><p>Both prevalence and incidence of the metabolic syndrome is very high in women with polycystic ovary syndrome (PCOS). Obesity and visceral fat enlargement play a dominant role in determining the final phenotype of PCOS. Androgen excess and insulin resistance may be responsible for the development of all features of the metabolic syndrome. The major factors responsible for this association seem to be related to a triumvirate including androgen excess, insulin resistance and associated hyperinsulinemia, and obesity, particularly the abdominal-visceral phenotype. With respect to obesity, it can be suggested that the association may be bidirectional, in the sense that obesity can worsen the phenotype of PCOS when present and can also be responsible for the development of a secondary form of PCOS even in susceptible subjects. In spite of the strong association among a long list of cardiovascular risk factors, there is no evidence that women with PCOS may be affected by an increased risk for cardiovascular mortality. Future research should carry out a detailed investigation into the potential role of androgen excess in determining the insulin resistant state and, specifically, the very high risk of developing type 2 diabetes.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"114-130"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000485995","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36216479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Syndrome in Parathyroid Diseases.","authors":"Sabrina Corbetta, G Mantovani, A Spada","doi":"10.1159/000486003","DOIUrl":"https://doi.org/10.1159/000486003","url":null,"abstract":"<p><p>Parathyroid glands are the main regulator of body mineral metabolism through parathormone (PTH) actions on bone and kidney. Experimental evidence suggests that PTH may have non-classical target organs such as adipose tissue, arterial vascular wall, cardiac muscle cells, and adrenal cortex cells, where it may play a role in controlling body energy, blood pressure, and metabolism. Cardiometabolic features have been investigated in the wide spectrum of clinical parathyroid disorders, from hyperparathyroidism to pseudohypoparathyroidism and hypoparathyroidism. Indeed, in parathyroid disorders, besides altered PTH secretion, impaired serum calcium levels and vitamin D status occur. Both calcium and vitamin D have been shown to regulate metabolism and to be associated with cardiovascular diseases. However, despite the complexity of parathyroid disorders, features of metabolic syndrome, such as obesity, insulin resistance, and glucose intolerance, arterial blood hypertension, and dyslipidemia, are frequently diagnosed in primary and secondary hyperparathyroidism as well as in pseudohyperparathyroidism. Here, we reviewed the most consistent data highlighting challenges and providing clinical remarks.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"67-84"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36216662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giulia Rastrelli, Sandra Filippi, Alessandra Sforza, Mario Maggi, Giovanni Corona
{"title":"Metabolic Syndrome in Male Hypogonadism.","authors":"Giulia Rastrelli, Sandra Filippi, Alessandra Sforza, Mario Maggi, Giovanni Corona","doi":"10.1159/000485999","DOIUrl":"https://doi.org/10.1159/000485999","url":null,"abstract":"<p><p>Metabolic syndrome (MetS) and hypogonadism (HG) are frequently comorbid. In this review, we summarize interconnections between the construct of MetS and the presence of HG, as well as the effect of specific treatments for each condition on this association. Data from meta-analytic studies suggest a bidirectional pathogenic relationship. In fact, reduced T (-2.21 [-2.43 to -1.98] nmol/L) at baseline predicts incident MetS. On the other hand, MetS at study entry increases the risk of developing HG (OR 2.46 [1.77-3.42]). The bidirectional pathogenic link between MetS and HG is further confirmed by the fact that treating MetS with insulin sensitizer is associated with an increase in T. In addition, a huge effect on increasing T is found in obese men undergoing procedures for losing weight, with more dramatic results obtained after bariatric surgery than after low calorie diet (increase in T 8.73 [6.51-10.95] nmol/L and 2.87 [1.68-4.07] nmol/L, respectively, according to a recent meta-analysis). On the other hand, there is evidence of an improvement in several metabolic derangements characterizing MetS in subjects treated with T. However, the latter results are still not conclusive and need further evidence from randomized clinical trials.</p>","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"49 ","pages":"131-155"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000485999","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36216659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
